Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term prognostic utility of computed tomography coronary angiography in older populations.
Gnanenthiran SR, Naoum C, Leipsic JA, Achenbach S, Al-Mallah MH, Andreini D, Bax JJ, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJW, Cury RC, DeLago A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufman PA, Kim YJ, Maffei E, Marques H, de Araújo Gonçalves P, Pontone G, Raff GL, Rubinshtein R, Shaw LJ, Villines TC, Gransar H, Lu Y, Jones EC, Peña JM, Lin FY, Kritharides L, Min JK. Gnanenthiran SR, et al. Among authors: kaufman pa. Eur Heart J Cardiovasc Imaging. 2019 Nov 1;20(11):1279-1286. doi: 10.1093/ehjci/jez067. Eur Heart J Cardiovasc Imaging. 2019. PMID: 30993334 Free article.
Site vs. core laboratory variability in computed tomographic angiography-derived SYNTAX scores in the SYNTAX III trial.
Katagiri Y, Andreini D, Miyazaki Y, Takahashi K, Komiyama H, Mushtaq S, Sonck J, Schoors D, Maisano F, Kaufman PA, Leal I, Lindeboom W, Piek JJ, Wykrzykowska JJ, Morel MA, Bartorelli AL, Onuma Y, Serruys PW; SYNTAX III REVOLUTION Investigators. Katagiri Y, et al. Among authors: kaufman pa. Eur Heart J Cardiovasc Imaging. 2021 Aug 14;22(9):1063-1071. doi: 10.1093/ehjci/jeaa172. Eur Heart J Cardiovasc Imaging. 2021. PMID: 32888011 Clinical Trial.
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Kalinsky K, et al. Among authors: kaufman pa. J Clin Oncol. 2024 Dec 18:JCO2402086. doi: 10.1200/JCO-24-02086. Online ahead of print. J Clin Oncol. 2024. PMID: 39693591
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Yonemori K, Boni V, Min KG, Meniawy TM, Lombard J, Kaufman PA, Richardson DL, Bender L, Okera M, Matsumoto K, Giridhar KV, García-Sáenz JA, Prenen H, de Speville Uribe BD, Dizon DS, Garcia-Corbacho J, Van Nieuwenhuysen E, Li Y, Estrem ST, Nguyen B, Bacchion F, Ismail-Khan R, Jhaveri K, Banda K. Yonemori K, et al. Among authors: kaufman pa. Gynecol Oncol. 2024 Dec;191:172-181. doi: 10.1016/j.ygyno.2024.10.006. Epub 2024 Oct 22. Gynecol Oncol. 2024. PMID: 39442371 Free article. Clinical Trial.
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, Carter S, Bidard FC, Fasching PA, Aftimos P, Wheatley D, Hamilton E, Aft R, Kulkarni S, Schmid P, Bhave M, Ismail-Khan R, Karacsonyi C, Estrem ST, Nguyen B, Ozbek U, Yuen E, Rodrik-Outmezguine V, Ciruelos E. Neven P, et al. Among authors: kaufman pa. Clin Cancer Res. 2024 Dec 2;30(23):5304-5313. doi: 10.1158/1078-0432.CCR-24-2113. Clin Cancer Res. 2024. PMID: 39377773 Free PMC article. Clinical Trial.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. Jhaveri KL, et al. Among authors: kaufman pa. J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6. J Clin Oncol. 2024. PMID: 39241211 Free PMC article. Clinical Trial.
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Goyal RK, et al. Among authors: kaufman pa. Breast Cancer (Dove Med Press). 2023 Nov 17;15:855-865. doi: 10.2147/BCTT.S422025. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 38020049 Free PMC article.
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martin M. Goetz MP, et al. Among authors: kaufman pa. Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573. Clin Cancer Res. 2024. PMID: 37889120 Free PMC article. Clinical Trial.
132 results